Form 4: Theravance Biopharma Director Receives Annual Equity Grants

Director Deepika Pakianathan was granted 6,009 ordinary shares and 13,398 stock options as part of her compensation for service on the board.

Summary

• Director Deepika Pakianathan acquired 6,009 ordinary shares on June 12, 2026, at no cost, likely as a restricted stock grant.
• The reporting person also received 13,398 share options with an exercise price of $16.64 per share.
• Following these transactions, the director directly owns 64,074 ordinary shares and 13,398 derivative securities.
• The options are scheduled to vest in 1/12th increments monthly or fully upon the next annual meeting of shareholders.
• The options carry an expiration date of June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing that confirms standard director compensation without signaling a change in corporate strategy.

Positives

• Insider alignment with shareholder interests through equity-based compensation.
• Long-term commitment indicated by a 10-year expiration window on stock options.
• Director maintains a significant direct ownership stake of over 64,000 shares.

Negatives

• Potential for minor shareholder dilution upon the vesting and exercise of the 13,398 options.
• The exercise price of $16.64 sets a high bar for the options to be 'in the money' if the current market price is significantly lower.

Risks

• Market volatility may prevent the share price from reaching the $16.64 exercise price before expiration in 2036.
• Vesting is contingent upon continuous service, posing a risk to the director's total compensation if board service is terminated.

Future Outlook

The grant of equity suggests a standard continuation of board governance and director incentivization for the upcoming fiscal year.

Management Comments

• The options shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is a standard practice in the biotechnology sector to preserve cash while aligning board members with long-term clinical and regulatory milestones.

Comparison to Industry Standards

• The 10-year option term is consistent with standard executive and director compensation packages in the NASDAQ Biotechnology Index.
• The monthly vesting schedule is a common mechanism used by mid-cap biotech firms like Ironwood Pharmaceuticals or Innoviva to ensure director retention.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution but benefit from the continued service of an experienced director.
• The Director receives increased equity exposure to the company's performance.

Next Steps

• Monthly vesting of 1/12th of the granted options starting July 2026.
• Full vesting of remaining options at the next annual meeting of shareholders.

Key Dates

Recommendation

This is a routine Form 4 filing for director compensation and does not provide new material information regarding the company's clinical pipeline or financial performance that would warrant a change in investment rating.

Keywords

Theravance Biopharma, TBPH, Insider Trading, Form 4, Deepika Pakianathan, Stock Options, Director Compensation, Biotechnology